Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Alan H Bryce¹, Neeraj Agarwal², Himisha Beltran³, Maha H Hussain⁴, Oliver Sartor⁵, Neal Shore⁶, Emmanuel S Antonarakis⁷, Andrew J Armstrong⁸, Jeremie Calais⁹, Michael A Carducci¹⁰, Tanya Barauskas Dorff¹¹, Jason A Efstathiou¹², Martin Gleave¹³, Leonard G Gomella¹⁴, Celestia Higano¹⁵, Thomas A Hope¹⁶, Andrei Iagaru¹⁷, Alicia K Morgans¹⁸, David S Morris¹⁹, Michael J Morris²⁰, Daniel P Petrylak²¹, Robert E Reiter²², Matthew B Rettig^{23

24

25}, Charles J Ryan²⁶, Scott B Sellinger²⁷, Daniel E Spratt²⁸, Sandy Srinivas²⁹, Scott T Tagawa³⁰, Mary-Ellen Taplin¹⁸, Evan Y Yu³¹, Tian Zhang³², Rana R McKay^{33

34}, Phillip J Koo³⁵, E David Crawford³³

Affiliations

¹ Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, Arizona, USA.
² Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
³ Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁴ Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA.
⁵ Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
⁶ Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA.
⁷ Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
⁸ Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
⁹ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, USA.
¹⁰ Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA.
¹¹ City of Hope Comprehensive Cancer Center, Duarte, California, USA.
¹² Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹³ Urological Sciences, Vancouver Prostate Center, University of British Columbia, Vancouver, British Columbia, Canada.
¹⁴ Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
¹⁵ Madrona Oncology, Seattle, Washington, USA.
¹⁶ Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
¹⁷ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California, USA.
¹⁸ Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
¹⁹ Urology Associates PC, Nashville, Tennessee, USA.
²⁰ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
²¹ Yale New Haven Health, New Haven, Connecticut, USA.
²² Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA.
²³ Division of Hematology-Oncology, Department of Medicine, VA Greater Los Angeles, Los Angeles, California, USA.
²⁴ Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
²⁵ Department of Urology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
²⁶ Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
²⁷ Advanced Urology Institute, Tallahassee, Florida, USA.
²⁸ University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA.
²⁹ Division of Medical Oncology, Stanford University Medical Center, Stanford, California, USA.
³⁰ Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.
³¹ Division of Hematology and Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington, USA.
³² Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
³³ Department of Urology, University of California San Diego, La Jolla, California, USA.
³⁴ Department of Medicine, University of California San Diego, La Jolla, California, USA.
³⁵ Banner MD Anderson Cancer Center, Phoenix, Arizona, USA.

PMID: 39616467
PMCID: PMC11694557
DOI: 10.1002/cncr.35612

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Alan H Bryce et al. Cancer. 2025.

. 2025 Jan 1;131(1):e35612.

doi: 10.1002/cncr.35612. Epub 2024 Dec 1.

Authors

Affiliations

¹ Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, Arizona, USA.
² Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
³ Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁴ Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA.
⁵ Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
⁶ Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA.
⁷ Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
⁸ Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
⁹ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, USA.
¹⁰ Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA.
¹¹ City of Hope Comprehensive Cancer Center, Duarte, California, USA.
¹² Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹³ Urological Sciences, Vancouver Prostate Center, University of British Columbia, Vancouver, British Columbia, Canada.
¹⁴ Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
¹⁵ Madrona Oncology, Seattle, Washington, USA.
¹⁶ Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
¹⁷ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California, USA.
¹⁸ Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
¹⁹ Urology Associates PC, Nashville, Tennessee, USA.
²⁰ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
²¹ Yale New Haven Health, New Haven, Connecticut, USA.
²² Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA.
²³ Division of Hematology-Oncology, Department of Medicine, VA Greater Los Angeles, Los Angeles, California, USA.
²⁴ Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
²⁵ Department of Urology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
²⁶ Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
²⁷ Advanced Urology Institute, Tallahassee, Florida, USA.
²⁸ University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA.
²⁹ Division of Medical Oncology, Stanford University Medical Center, Stanford, California, USA.
³⁰ Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.
³¹ Division of Hematology and Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington, USA.
³² Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
³³ Department of Urology, University of California San Diego, La Jolla, California, USA.
³⁴ Department of Medicine, University of California San Diego, La Jolla, California, USA.
³⁵ Banner MD Anderson Cancer Center, Phoenix, Arizona, USA.

PMID: 39616467
PMCID: PMC11694557
DOI: 10.1002/cncr.35612

Abstract

Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.

Keywords: advanced prostate cancer; androgen receptor pathway inhibitors; biochemical recurrence; consensus recommendations; poly(ADP‐ribose) polymerase (PARP) inhibitors; radioligand therapy.

PubMed Disclaimer

Conflict of interest statement

Alan H. Bryce reports grants/contracts from Janssen Pharmaceuticals; personal/consulting or advisory fees from Astellas Pharma, AstraZeneca, Bayer, Janssen Pharmaceuticals, Merck, Myovant Sciences, Novartis, and Pfizer; and service on a Data and Safety Monitoring Board for Lantheus Medical Imaging Inc. outside the submitted work. Neeraj Agarwal reports institutional research funding from Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer HealthCare Pharmaceuticals Inc. (Bayer), Bristol Myers Squibb (BMS), Calithera, Celldex, Clovis Oncology, Crispr, Eisai, Eli Lilly & Company, EMD Serono, Exelixis, Genentech, Gilead Sciences, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon; and personal/consulting or advisory fees from Astellas, AstraZeneca, AVEO Pharmaceuticals, Bayer, BMS, Calithera, Clovis Oncology, Eisai, Eli Lilly & Company, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead Sciences, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics outside the submitted work. Himisha Beltran reports institutional research funding from Janssen, BMS, Circle Pharma, Daiichi Sankyo, and Novartis; personal/consulting or advisory fees from Amgen, Astellas Pharma US, AstraZeneca, Bayer, Blue Earth Diagnostics Ltd., Curie Therapeutics, Daichi Sankyo, Foundation Medicine, Fusion Pharma, Janssen, LOXO, Merck, Novartis, Pfizer, Oncorus, and Sanofi Genzyme; and service on a Data Safety and Monitoring Board for AstraZeneca outside the submitted work. Maha H. Hussain reports institutional research/grant funding from Astellas Pharma, AstraZeneca, Arvinas, Bayer, Celgene, Corcept, Covergent Therapeutics Inc., Janssen, Novartis, and Roche; personal/consulting or advisory fees from Glaxo Smith Kline, Novartis, and Bayer; and honoraria for educational events or lectures from Academic CME, Merck, MJH Life Sciences, Mubarak Mahdi Almansour (Chairman, International Genitourinary Cancer Conference), and Academic CME outside the submitted work. Oliver Sartor reports institutional research/grant funding from Advanced Accelerator Applications (AAA), Amgen, ARTbio, Astellas Pharma, AstraZeneca, Bayer, InVitae, Janssen, Lantheus Medical Imaging, Merck, and Sanofi; personal/consulting or advisory fees from AAA, Amgen, ART BioScience, Astellas Pharma, AstraZeneca, Bayer, BMS, Clarity Pharmaceuticals, Daiichi Sankyo, Exelixis, EMD Serono, Fusion Pharmaceuticals, Genzyme Corporation, HengruiTherapeutics AG, Invitae, Isotopen Technologies Meunchen, Janssen, MacroGenics, Merck, Morphimmune, Moyvant, Myriad Genetic Laboratories Inc., Noria Therapeutics, Novartis, Noxopharm, Pfizer, Point Biopharma, Progenics Pharmaceuticals Inc., Ratio, Sanofi and Genzyme US Companies, Taiho Pharmaceutical, Telix Pharmaceuticals, Tempus, TeneoBio, Tessa Therapeutics, and Theragnostics; stock or other ownership interest in AbbVie, Cardinal Health, Clarity Pharmaceuticals, Convergent, Eli Lilly & Company, Fusion Pharmaceuticals, Point Biopharma, Ratio, Telix Pharmaceuticals, and United Health Group; patents for Saposin C and receptors as targets for treatment of benign and malignant disorders (US patent awarded January 23, 2007; patent no. 7,166,691); fees for expert testimony from Sanofi; and reimbursement for travel, accommodations, or expenses from AstraZeneca, Bayer, Lantheus Medical Imaging, and Sanofi, all outside the submitted work. Neal Shore reports personal/consulting or advisory fees from AbbVie, Accord, Alessa Therapeutics, Akido, Amgen, Antev, Arquer, Asieris, Astellas Pharma, AstraZeneca, Aura Biosciences, Bayer, Bioprotect, BMS, Boston Scientific Corporation, Clarity Medical System, Clovis Oncology, Cold Genesys, Dendreon Pharmaceuticals LLC, Eli Lilly & Company, Ferring Pharmaceuticals Ltd., Exact Images, Exact Sciences, FerGene, FIZE Medical, GC Oncology, GenesisCare, Genetech, Guardant, Ferring, Fize Medical, Foundation Medicine Inc., ImmunityBio, Incyte, Invitae, Janssen Biotech, Lantheus Medical Imaging, MDXhealth, Merck, Minomic, Myovant Sciences, Myriad, NGM, Nonagen, Novartis Gene Therapies Inc. (aka AveXix Inc.), NYMOX, Pacific Edge, Photocure Inc., Pfizer, PreView, PlatformQ, Profound, Promaxo, Propella, Protara, Sanofi US Services Inc., SesenBio, Siemens, Specialty Networks, Sumitovant, Telix, Tolmar Pharmaceuticals Inc., Urogen Pharma Inc., Vaxiion, and Vessi; payment for expert testimony from Ferring; and is on the board of Photocure Inc., all outside the submitted work. Emmanuel S. Antonarakis reports grants from Celgene, Novartis, and Orion Corporation; grants and personal/consulting or advisory fees from Astellas Pharma, AstraZeneca, Bayer, Clovis Oncology, Curium, Janssen Pharmaceuticals, MacroGenics, Merck, Pfizer, and Sanofi; personal/consulting or advisory fees from Aadi Biosciences, Aikido Pharma, Amgen, Astellas Pharma, Blue Earth Diagnostics Ltd., Corcept Therapeutics, Eli Lilly & Company, Exact Sciences, Foundation Medicine Inc., Hookipa Pharma, Invitae, Menarini‐Silicon Biosystems Inc., Sanofi, Tango Therapeutics, Tempus, and z‐Alpha; and has a patent for an AR‐V7 biomarker technology that has been licensed to Qiagen LLC, all outside the submitted work. Andrew J. Armstrong reports institutional research funding from Amgen, Astellas Pharma, AstraZeneca, Bayer, BMS, Celgene, Dendreon Pharmaceuticals LLC, Forma, Janssen Pharma, Novartis, and Pfizer; and personal/consulting or advisory fees from Astellas Pharma, AstraZeneca, Bayer, BMS, Celgene, Clovis Oncology, Dendreon Pharmaceuticals LLC, Epic Sciences, Exact Sciences, Exelixis, Forma, Genomic Health, GoodRx, Janssen Biotech, Myovant Sciences, Novartis, and Pfizer outside the submitted work. Jeremie Calais reports research grant funding from Lantheus Medical Imaging, Novartis, and POINT Biopharma; and personal/consulting or advisory fees from Amgen, Astellas, Bayer, Blue Earth Diagnostics Ltd., Curium Pharma, DS Pharma, Fibrogen, GE Healthcare, Isoray, IBA RadioPharma, Janssen Pharmaceuticals Inc., Lightpoint Medical, Lantheus Medical Imaging, Monrol, Novartis, Pfizer, POINT Biopharma, Radiomedix, Sanofi, Siemens‐Varian, SOFIE, and Telix Pharmaceuticals outside the submitted work. Tanya Barauskas Dorr reports personal/consulting or advisory fees from AstraZeneca, Bayer, Janssen, and Sanofi outside the submitted work. Jason A. Efstathiou reports personal/consulting or advisory fees from AngioDynamics Inc., Astellas Pharma, AstraZeneca, Blue Earth Diagnostics Ltd., Bayer, Boston Scientific Corporation, Clarity Pharmaceuticals, Elekta Inc., Genentech USA Inc., Gilead Sciences, IBA Proton Therapy Inc., Janssen Biotech Inc., Lantheus Medical Imaging, Merck, Myovant Sciences, Pfizer Pharmaceuticals LLC, Progenics Pharmaceuticals Inc.; and support for other professional activities from Merck, Myovant Sciences, and Roivant Pharma outside the submitted work. Martin Gleave reports personal/consulting or advisory fees from AbCellera Biologics, Astellas Pharma, AstraZeneca, Bayer, Janssen Pharmaceuticals Inc., Pfizer, and Sanofi outside the submitted work and owns stock in Sustained Therapeutics. Leonard G. Gomella reports personal/consulting or advisory fees from AstraZeneca, Blue Earth Diagnostics Ltd., Janssen Pharmaceuticals Inc., Lantheus Medical Imaging, and Merck outside the submitted work. Celestia Higano reports personal/consulting or advisory fees from Pfizer and service on a Data Safety and Monitoring Board at AstraZeneca, Exelixis Inc. outside the submitted work. Thomas A. Hope reports grants/contracts from Janssen Pharmaceuticals, Lantheus Medical Imaging, Novartis, and Telix Pharmaceuticals; personal/consulting or advisory fees from Bayer, Cardinal Health Inc., and Curium; support for other professional activities from Blue Earth Diagnostics Ltd., Ipsen Bioscience Inc., and RayzeBio; and owns stock options in Rayze Bio outside the submitted work. Andrei Iagaru reports grants/contracts from GE Healthcare, Novartis Pharmaceuticals Corporation, and Progenics Pharmaceuticals Inc.; personal/consulting or advisory fees from Novartis Pharmaceuticals Corporation, Progenics Pharmaceuticals Inc., RayzeBio, and Telix; support for other professional activities from Alpha9Tx, Clarity Pharmaceuticals, GE Healthcare, and Radionetics Oncology; and travel support from GE Healthcare outside the submitted work. Alicia K. Morgans reports research funding from Astellas Pharma, Bayer, Janssen Pharmaceuticals, Myovant Sciences, Pfizer, and Sanofi; and personal/consulting or advisory fees from AAA, Astellas Pharma, AstraZeneca, Bayer, Blue Earth Diagnostics Ltd., Clovis Oncology, Curium, Dendreon Pharmaceuticals LLC, Ely Lilly & Company, Exelixis, Gilead Sciences, Janssen Pharmaceuticals, Lantheus Medical Imaging, Macrogenetics, Merck, Myovant Sciences, Neomorph, Novartis, Pfizer, Sanofi‐Aventis US LLC, Seattle Genetics, and Telex outside the submitted work. David S. Morris reports meeting participation/lecture fees from Pfizer; personal/consulting or advisory fees from Astellas Pharma, AstraZeneca, Bayer, Blue Earth Diagnostics Ltd., Clovis Oncology, Decipher Biosciences Inc., Dendreon Pharmaceuticals LLC, Janssen Biotech Inc., Lantheus Medical Imaging, Merck, Novartis, Pfizer, Tempus, Tolmar Pharmaceuticals Inc., and UroGOP LLC; and stock ownership in UroGOP LLC outside the submitted work. Michael J. Morris reports personal/consulting or advisory fees from AAA, Amgen, Arvinas, AstraZeneca, Bayer, Blue Earth Diagnostics Ltd., Celgene, Clarity Pharmaceuticals, Convergent Therapeutics, Daiichi Sankyo Company, Exelixis, Flare Therapeutics, Fusion Pharma, Lantheus Medical Imaging, ITM Isotope Technologies, ITM Oncologics GmbH, Novartis, Pfizer, POINT Biopharma, Pfizer, Progenics, Telix, and z‐Alpha; and service as an uncompensated advisor to Bayer and Novartis all outside the submitted work. Daniel P. Petrylak reports grants/contracts from Ada Cap (AAA), AgenSys Inc., Arvinas, Astellas Pharma, AstraZeneca, Bayer, Bicycle Therapeutics, Bio Xcel Therapeutics, BMS, Clovis Oncology Inc., Daiichi Sankyo Company Ltd., Eisai Inc., Eli Lilly & Company, Endocytic, Ferring, Genentech, Gilead Sciences, Indocin, MedImmune, Medivation, Merck, Mirati, Novartis Pharma, Pfizer, Progenics, Replimune, Roche Laboratories, Sanofi US Services Inc., and Seattle Genetics; personal/consulting or advisory fees from Ada Cap (AAA), Amgen, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Clovis Oncology, Eli Lilly & Company, Exelixis, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Ipsen, Insight Corporation, Janssen Biotech Inc., Merck & Company Inc, Mirati, Monopteros, Pfizer, Pharmacyclics LLC, Regeneron, Roche Laboratories, Sanofi Aventis Pharmaceuticals, Seattle Genetics, and UroGen Pharma; support for other professional activities from Bicycle Therapeutics and Merck; and has owned stock in Bellicum and Tyme outside the submitted work. Robert E. Reiter reports institutional research funding from Artera AI, AstraZeneca, Bayer, BMS, Exelixis, Oncternal, and Tempus; and consulting/personal fees from Ambrx, Arcus, AstraZeneca, AVEO Pharmaceuticals, Bayer, Blue Earth Diagnostics Ltd., BMS, Calithera, Caris, Dendreon, Eli Lilly & Company, Exelixis, Johnson & Johnson, Lantheus Medical Imaging, Merck, Myovant Sciences, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, and Tempus outside the submitted work. Matthew B. Rettig reports institutional grants/research support from Johnson & Johnson and Merck; grants/research support from Amgen, Clovis Oncology, Lantheus Medical Imaging, ORIC, Novartis, Pfizer, and Progenics; personal/consulting or advisory fees from AVEO Pharmaceuticals, Bayer, Immune Bio, Johnson & Johnson, Lantheus Medical Imaging, Myovant Sciences, and Novartis; and is a Speakers' Bureau member at Bayer and Johnson & Johnson outside the submitted work. Scott B. Sellinger reports personal/consulting or speaking fees from Astellas Pharma, AstraZeneca, Bayer, Foundation Medicine Inc., Janssen Pharmaceuticals Inc., Johnson & Johnson, MDX Health, Merck, Pfizer, and Tempus outside the submitted work. Daniel E. Spratt reports personal/consulting or advisory fees from Astellas Pharma, AstraZeneca, Bayer, Boston Scientific Corporation, Elekta, Janssen Biotech Inc., Novartis, Pfizer Inc., and Varian outside the submitted work. Sandy Srinivas reports personal/consulting or advisory fees from Janssen Pharmaceuticals Inc. and Novartis outside the submitted work. Scott T. Tagawa reports institutional research funding from AbbVie, Ambrx, Amgen, Astellas Pharma, AstraZeneca, Atlab, AVEO Pharmaceuticals, Bayer, BMS, Boehringer Ingelheim, Clarity Pharmaceuticals, Clovis Oncology, Dendreon, Eli Lilly & Company, Endocyte, Genentech, Gilead Sciences, Immunomedics, Inovio, Janssen, Karyopharm, Medivation, Merck, Millennium, Newlink, Novartis, POINT Biopharma, Progenics, Rexahn, Sanofi, and Seattle Genetics; personal/consulting or advisory fees from AAA/Novartis, AbbVie, Aikido Pharma, Ambrx, Amgen Inc., Astellas Pharma, Bayer, Blue Earth Diagnostics Ltd., Clarity Pharmaceuticals, Clovis Oncology Inc., Convergent Therapeutics, Daiichi Sankyo, Dendreon, Eisai Inc., EMD Serono, Endocyte, Genentech, Genomic Health, Gilead Sciences, Immunomedics, Janssen Biotech, Karyopharm, Medivation, Merck, Myovant Sciences, Novartis, Pfizer, POINT Biopharma, QED, Regeneron, Sanofi, Seattle Genetics, Telix Pharmaceuticals, Tolmar Pharmaceuticals Inc., and TransThera; unpaid work as a consultant for Ambrx, Amgen, Atlab Pharma, and Phosplatin Therapeutics; service on a Data Safety and Monitoring Board for Boston Scientific Corporation; owns stock options in Covergent Therapeutics; and his institution holds patents for biomarkers for sacituzumab govitecan therapy (Immunomedics/Gilead), all outside the submitted work. Mary‐Ellen Taplin personal/consulting or advisory fees from Arcus Bioscience, Arvinas, Astellas Pharma, AstraZeneca, Blue Earth Therapeutics, Flare Therapeutics, Geode Therapeutics, Interpubic GIS, Janssen Pharmaceuticals Inc., Laekna Therapeutics, MJH Life Sciences, Pfizer, Physicians Education Resources LLC, Propella Therapeutics, Wiley, and Wolters Kluwer; service on a Data Safety and Monitoring Board at Clovis Oncology; and support for other professional services from Janssen Pharmaceuticals Inc. outside the submitted work. Evan Y. Yu reports institutional research funding from Bayer, Blue Earth Diagnostics Ltd., Daiichi‐Sankyo, Dendreon, Lantheus Medical Imaging, Merck, Seagen, Surface, Taiho, and Tyra; and personal/consulting or advisory fees from AAA, Aadi Bioscience, Bayer, BMS, Loxo Oncology, Janssen Global Services LLC, Merck, Novartis, and Oncternal outside the submitted work. Tian Zhang reports principal investigator/research funding from ALX Oncology, Astellas Pharma, AstraZeneca, Eli Lilly & Company, FBD Biologics, Guardant, Janssen Pharmaceuticals Inc., Janux Therapeutics, Merck, OncoC4, Pfizer, and Tempus; personal/consulting or advisory fees from Amgen, Aptitude Health, Aravive, AstraZeneca, AVEO Oncology, Bayer, BMS, Caris Life Sciences, Eisai Inc., Eli Lilly & Company, EMD Serono, Exelixis, Gilead Sciences, Janssen Pharmaceuticals Inc., Mashup Media, Merck, MJH Associates, Novartis, PeerView, Pfizer, Seagen Inc., Sanofi‐Aventis, and Vaniam; and travel support from Bayer outside the submitted work; in addition, her spouse is founder and has part ownership in Capio Biosciences and Archimmune Therapeutics. Rana R. McKay reports personal/consulting or advisory fees from Ambrx, Arcus Bioscience, AstraZeneca, Bayer, Blue Earth Diagnostics Ltd., Calithera, Caris, Dendreon Pharmaceuticals LLC, Eisai Inc., Eli Lilly & Company, Exelixis, Janssen Biotech, Merck, Myovant Sciences, Neomorph, Novartis, Pfizer, Sanofi US Services Inc., Sorrento Therapeutics, Telix, Tempus, and Vividion outside the submitted work. Phillip J. Koo reports personal/consulting or advisory fees from Astellas Pharma, AstraZeneca, Bayer, Blue Earth Diagnostics Ltd., BMS, Clarity, Curium US LLC, Lantheus Medical Imaging, Merck, Janssen Biotech Inc., Novartis, Pfizer, Sanofi, and Telix outside the submitted work. E. David Crawford reports research/grant funding from the National Institutes of Health and the University of Colorado Cancer Center; personal/consulting or advisory fees from Astellas Pharma, Bayer, Carden Jennings, Janssen Biotech Inc., MDx, Pfizer, and Tolmar Pharmaceuticals Inc.; service on a Data Safety and Monitoring Board at Bayer HealthCare Pharmaceuticals; and compensation for a leadership position from Carden Jennings outside the submitted work. Michael Carducci and Charles J. Ryan disclosed no conflicts of interest. RRM has received institutional research funding from Artera AI, AstraZeneca, Bayer, BMS, Exelixis, Oncternal, and Tempus; and has received consulting fees from Ambrx, Arcus, AstraZeneca, Aveo, Bayer, Blue Earth Diagnostics Ltd., BMS, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, and Tempus.

Figures

**FIGURE 1**
Homologous recombination repair gene mutations considered sensitive to (A) poly(ADP‐ribose) polymerase inhibitor monotherapy or (B) poly(ADP‐ribose) polymerase inhibitor/androgen receptor pathway inhibitor combination therapy.

See this image and copyright information in PMC

References

1. National Comprehensive Cancer Network (NCCN) . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer. Version 3.2024. NCCN; 2024. Accessed April 8, 2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
1. Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082‐1090. doi:10.1097/JU.0000000000003452 - DOI - PubMed
1. Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline. Part I: introduction and treatment decision‐making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024;211(4):509‐517. doi:10.1097/JU.0000000000003892 - DOI - PubMed
1. Virgo KS, Rumble RB, Talcott J. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2023;41(20):3652‐3656. doi:10.1200/JCO.23.00155 - DOI - PubMed
1. Gillessen S, Bossi A, Davis ID, et al. Management of patients with advanced prostate cancer. Part I: intermediate‐/high‐risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023;83(3):267‐293. doi:10.1016/j.eururo.2022.11.002 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Affiliations

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical